retatrutide clinical trial results obesity VisualAbstract: reduces body weight by 17.5% in patients with Triple hormone receptor agonist retatrutide
Description
It is still unknown how stress influences central GLP-1R signaling in metabolic pathologies, such as obesity or diabetes
These findings underscore the potential of semaglutide to be an effective treatment option, but given the broad effects, there remains a need to establish optimal dosing regimens to ensure long-term safety and efficacy for pediatric and adult patients
Reply The prior authorization process for the Bridge Program has not yet been made fully available
Individual experience only
